{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:24Z","timestamp":1786982124592,"version":"build-2736575974"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF). Despite advances in disease-modifying therapy, the mainstay of treatment for congestion\u2014loop diuretics\u2014has remained largely unchanged for 50 years. In these two articles (part I: loop diuretics and part II: combination therapy), we will review the history of diuretic treatment and the current trial evidence for different diuretic strategies and explore potential future directions of research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>We will assess recent trials including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF amongst others, and assess how these may influence current practice and future research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>There are few data on which to base diuretic therapy in clinical practice. The most robust evidence is for high dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF, yet this is not reflected in guidelines. There is an urgent need for more and better research on different diuretic strategies in patients with HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11897-024-00643-3","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T01:02:32Z","timestamp":1705626152000},"page":"101-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions \u2013 Part I: Loop Diuretics"],"prefix":"10.1007","volume":"21","author":[{"given":"Joseph James","family":"Cuthbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"6","key":"643_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10557-016-6697-7","volume":"30","author":"P Pellicori","year":"2016","unstructured":"Pellicori P, Cleland JG, Zhang J, Kallvikbacka-Bennett A, Urbinati A, Shah P, Kazmi S, Clark AL. Cardiac dysfunction, congestion and loop diuretics: their relationship to prognosis in heart failure. Cardiovasc Drugs Ther. 2016;30(6):599\u2013609. https:\/\/doi.org\/10.1007\/s10557-016-6697-7.","journal-title":"Cardiovasc Drugs Ther"},{"key":"643_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijcard.2019.03.020","volume":"285","author":"A Shoaib","year":"2019","unstructured":"Shoaib A, Mamas MA, Ahmad QS, et al. Characteristics and outcome of acute heart failure patients according to the severity of peripheral oedema. Int J Cardiol. 2019;285:40\u20136. https:\/\/doi.org\/10.1016\/j.ijcard.2019.03.020.","journal-title":"Int J Cardiol"},{"issue":"12","key":"643_CR3","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/ejhf.153","volume":"16","author":"A Shoaib","year":"2014","unstructured":"Shoaib A, Waleed M, Khan S, et al. Breathlessness at rest is not the dominant presentation of patients admitted with heart failure. Eur J Heart Fail. 2014;16(12):1283\u201391. https:\/\/doi.org\/10.1002\/ejhf.153.","journal-title":"Eur J Heart Fail"},{"key":"643_CR4","unstructured":"National Institute for Cardiovascular Outcomes Research. National Heart Failure Audit. 2022 summary report. Available from: NHFA-DOC-2022-FINAL.pdf (nicor.org.uk) [Accessed 22\/09\/2023]."},{"issue":"12","key":"643_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574\u201385. https:\/\/doi.org\/10.1002\/ejhf.813.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"643_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"\u2022 Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137\u201355. https:\/\/doi.org\/10.1002\/ejhf.1369. A useful summary of agreed \u201cbest practice\u201d with diuretic treatment from the ESC","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"643_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/ejhf.507","volume":"18","author":"J Butler","year":"2016","unstructured":"Butler J, Gheorghiade M, Metra M. Moving away from symptoms-based heart failure treatment: misperceptions and real risks for patients with heart failure. Eur J Heart Fail. 2016;18(4):350\u20132. https:\/\/doi.org\/10.1002\/ejhf.507.","journal-title":"Eur J Heart Fail"},{"key":"643_CR8","doi-asserted-by":"publisher","first-page":"ehad195","DOI":"10.1093\/eurheartj\/ehad195","volume":"25","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;25:ehad195. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J."},{"issue":"258","key":"643_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijcard.2018.01.067","volume":"1","author":"J Rubio-Gracia","year":"2018","unstructured":"Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O\u2019Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, Damman K, P\u00e9rez-Calvo JI, Voors AA. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;1(258):185\u201391. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.067.","journal-title":"Int J Cardiol"},{"issue":"13","key":"643_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"\u2022 Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Ter Maaten JM, Damman K, Lassus J, Mebazaa A, Filippatos G, Ruschitzka F, Dupont M, ADVOR Study Group. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387(13):1185\u201395. https:\/\/doi.org\/10.1056\/NEJMoa2203094.\u00a0Largest trial of a\u00a0diuretic agent in patients admitted to hospital with heart failure; best evidence\u00a0to date that acetazolamide may be a usefull add-on diuretic treatment","journal-title":"N Engl J Med"},{"issue":"7","key":"643_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/ejhf.1383","volume":"21","author":"P Pellicori","year":"2019","unstructured":"\u2022 Pellicori P, Shah P, Cuthbert J, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 2019;21(7):904\u201316. https:\/\/doi.org\/10.1002\/ejhf.1383. Observational work that demonstrates many patients that have congestion without signs or symptoms on examination","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"643_CR12","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/ejhf.2353","volume":"23","author":"JJ Cuthbert","year":"2021","unstructured":"Cuthbert JJ, Pellicori P, Flockton R, et al. The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure. Eur J Heart Fail. 2021;23(11):1831\u201340. https:\/\/doi.org\/10.1002\/ejhf.2353.","journal-title":"Eur J Heart Fail"},{"key":"643_CR13","unstructured":"National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management NICE guideline [NG106]. Available from: Overview | Chronic heart failure in adults: diagnosis and management | Guidance | NICE. [Accessed: 03\/10\/2023]."},{"issue":"18","key":"643_CR14","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May 3;145(18):e1033] [published correction appears in Circulation. 2022 Sep 27;146(13):e185] [published correction appears in Circulation. 2023 Apr 4;147(14):e674]. Circulation. 2022;145(18):e895\u20131032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"key":"643_CR15","doi-asserted-by":"publisher","unstructured":"Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003838. https:\/\/doi.org\/10.1002\/14651858.CD003838.pub3. Update in: Cochrane Database Syst Rev. 2016;4:CD003838.","DOI":"10.1002\/14651858.CD003838.pub3"},{"issue":"5414","key":"643_CR16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/bmj.2.5414.910","volume":"2","author":"W Stokes","year":"1964","unstructured":"Stokes W. A new effective diuretic - Lasix. Br Med J. 1964;2(5414):910\u20134.","journal-title":"Br Med J"},{"key":"643_CR17","volume-title":"An account of the foxglove and some of its medical uses: with practical remarks on dropsy and other diseases","author":"W Withering","year":"1785","unstructured":"Withering W. An account of the foxglove and some of its medical uses: with practical remarks on dropsy and other diseases. London: GG J & J Robinson; 1785."},{"issue":"104","key":"643_CR18","first-page":"331","volume":"18","author":"JS Stringham","year":"1807","unstructured":"Stringham JS. On the diuretic effects of mercury in a case of syphilis. Med Phys J. 1807;18(104):331\u20133.","journal-title":"Med Phys J"},{"issue":"2","key":"643_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/hrt.3.2.112","volume":"3","author":"W Evans","year":"1941","unstructured":"Evans W, Paxon T. A comparison of the mercurial diuretics used in heart failure. Br Heart J. 1941;3(2):112\u201320.","journal-title":"Br Heart J"},{"issue":"21","key":"643_CR20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJM195305212482102","volume":"248","author":"CK Friedberg","year":"1953","unstructured":"Friedberg CK, Taymor R, Minor JB, Halpern M. The use of diamox, a carbonic anhydrase inhibitor, as an oral diuretic in patients with congestive heart failure. N Engl J Med. 1953;248(21):883\u20139. https:\/\/doi.org\/10.1056\/NEJM195305212482102.","journal-title":"N Engl J Med"},{"issue":"13","key":"643_CR21","first-page":"633","volume":"89","author":"BM Carruthers","year":"1963","unstructured":"Carruthers BM, Ledray RD, Seraglia M, Mcintosh HW, Walsh GC. Effect of an aldosterone antagonist (spironolactone) on patients with severe congestive heart failure. Can Med Assoc J. 1963;89(13):633\u201341.","journal-title":"Can Med Assoc J."},{"issue":"21","key":"643_CR22","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJM195711212572103","volume":"257","author":"GE Schreiner","year":"1957","unstructured":"Schreiner GE, Bloomer HA. Effect of chlorothiazide on the edema of cirrhosis, nephrosis, congestive heart failure and chronic renal insufficiency. N Engl J Med. 1957;257(21):1016\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"643_CR23","first-page":"53","volume":"53","author":"RV Ford","year":"1959","unstructured":"Ford RV, Rochelle JB 3rd. The differing mechanisms of action of mercurials, carbonic anhydrase inhibitors, and chlorothiazide as diuretic agents. J Lab Clin Med. 1959;53(1):53\u201363.","journal-title":"J Lab Clin Med"},{"issue":"6","key":"643_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.CIR.19.6.827","volume":"19","author":"W Hollander","year":"1959","unstructured":"Hollander W, Chobanian AV, Wilkins RW. Relationship between diuretic and antihypertensive effects of chlorothiazide and mercurial diuretics. Circulation. 1959;19(6):827\u201338.","journal-title":"Circulation"},{"issue":"6","key":"643_CR25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1185\/03007997609111998","volume":"4","author":"C Kourouklis","year":"1976","unstructured":"Kourouklis C, Christensen O, Augoustakis D. Bumetanide in congestive heart failure. Curr Med Res Opin. 1976;4(6):422\u201331. https:\/\/doi.org\/10.1185\/03007997609111998.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"643_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/clpt.1986.228","volume":"40","author":"LG Sherman","year":"1986","unstructured":"Sherman LG, Liang CS, Baumgardner S, Charuzi Y, Chardo F, Kim CS. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986;40(5):587\u201394. https:\/\/doi.org\/10.1038\/clpt.1986.228.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"643_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/BF01857763","volume":"4","author":"W Haerer","year":"1990","unstructured":"Haerer W, Bauer U, Sultan N, Cernoch K, Mouselimis N, Fehske KJ, Hetzel M, Stauch M, Hombach V. Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure\u2013a placebo-controlled trial. Cardiovasc Drugs Ther. 1990;4(2):515\u201321. https:\/\/doi.org\/10.1007\/BF01857763.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"Suppl 5","key":"643_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000174699","volume":"77","author":"FX Kleber","year":"1990","unstructured":"Kleber FX, Thyroff-Friesinger U. Treatment of mild chronic congestive heart failure with ibopamine, hydrochlorothiazide, ibopamine plus hydrochlorothiazide or placebo. A double-blind comparative study. Cardiology. 1990;77(Suppl 5):67\u201374. https:\/\/doi.org\/10.1159\/000174699.","journal-title":"Cardiology"},{"issue":"5","key":"643_CR29","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1161\/01.CIR.34.5.910","volume":"34","author":"WB Stason","year":"1966","unstructured":"Stason WB, Cannon PJ, Heinemann HO, Laragh JH. Furosemide. A clinical evaluation of its diuretic action. Circulation. 1966;34(5):910\u201320.","journal-title":"Circulation."},{"issue":"2","key":"643_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/030006058801600209","volume":"16","author":"RJ Crawford","year":"1988","unstructured":"Crawford RJ, Allman S, Gibson W, Kitchen S, Richards HH. A comparative study of frusemide-amiloride and cyclopenthiazide-potassium chloride in the treatment of congestive cardiac failure in general practice. J Int Med Res. 1988;16(2):143\u20139. https:\/\/doi.org\/10.1177\/030006058801600209.","journal-title":"J Int Med Res."},{"issue":"5473","key":"643_CR31","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1136\/bmj.2.5473.1277","volume":"2","author":"JH Stewart","year":"1965","unstructured":"Stewart JH, Edwards KD. Clinical comparison of frusemide with bendrofluazide, mersalyl, and ethacrynic acid. Br Med J. 1965;2(5473):1277\u201381. https:\/\/doi.org\/10.1136\/bmj.2.5473.1277.","journal-title":"Br Med J"},{"issue":"7","key":"643_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/j.1552-4604.1977.tb04625.x","volume":"17","author":"B Levy","year":"1977","unstructured":"Levy B. The efficacy and safety of furosemide and a combination of spironolactone and hydrochlorothiazide in congestive heart failure. J Clin Pharmacol. 1977;17(7):420\u201330. https:\/\/doi.org\/10.1002\/j.1552-4604.1977.tb04625.x.","journal-title":"J Clin Pharmacol"},{"issue":"2\u20133","key":"643_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/j.1552-4604.1979.tb02470.x","volume":"19","author":"EL Coodley","year":"1979","unstructured":"Coodley EL, Nandi PS, Chiotellis P. Evaluation of a new diuretic, diapamide, in congestive heart failure. J Clin Pharmacol. 1979;19(2\u20133):127\u201336. https:\/\/doi.org\/10.1002\/j.1552-4604.1979.tb02470.x.","journal-title":"J Clin Pharmacol."},{"issue":"664","key":"643_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/pgmj.57.664.71","volume":"57","author":"R Gabriel","year":"1981","unstructured":"Gabriel R, Baylor P. Comparison of the chronic effects of bendrofluazide, bumetanide and frusemide on plasma biochemical variables. Postgrad Med J. 1981;57(664):71\u20134. https:\/\/doi.org\/10.1136\/pgmj.57.664.71.","journal-title":"Postgrad Med J"},{"issue":"4","key":"643_CR35","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1185\/03007998809114241","volume":"11","author":"D Heseltine","year":"1988","unstructured":"Heseltine D, Bramble MG. Loop diuretics cause less postural hypotension than thiazide diuretics in the frail elderly. Curr Med Res Opin. 1988;11(4):232\u20135. https:\/\/doi.org\/10.1185\/03007998809114241.","journal-title":"Curr Med Res Opin"},{"key":"643_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-56-2-241","volume":"56","author":"AP Crosley Jr","year":"1962","unstructured":"Crosley AP Jr, Ronquillo LM, Strickland WH, Alexander F. Triamterene, a new natruretic agent. Preliminary observations in man. Ann Intern Med. 1962;56:241\u201351. https:\/\/doi.org\/10.7326\/0003-4819-56-2-241.","journal-title":"Ann Intern Med."},{"issue":"2","key":"643_CR37","first-page":"472","volume":"157","author":"JE Baer","year":"1967","unstructured":"Baer JE, Jones CB, Spitzer SA, Russo HF. The potassium-sparing and natriuretic activity of N-amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride dihydrate (amiloride hydrochloride). J Pharmacol Exp Ther. 1967;157(2):472\u201385.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8561","key":"643_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/s0140-6736(87)91074-9","volume":"2","author":"A Richardson","year":"1987","unstructured":"Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2(8561):709\u201311. https:\/\/doi.org\/10.1016\/s0140-6736(87)91074-9.","journal-title":"Lancet"},{"issue":"10","key":"643_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med."},{"issue":"1","key":"643_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1681\/ASN.2005090966","volume":"18","author":"M Hasegawa","year":"2007","unstructured":"Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol. 2007;18(1):37\u201345. https:\/\/doi.org\/10.1681\/ASN.2005090966.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"643_CR41","doi-asserted-by":"publisher","first-page":"17308","DOI":"10.1074\/jbc.M112.356014","volume":"287","author":"S Somasekharan","year":"2012","unstructured":"Somasekharan S, Tanis J, Forbush B. Loop diuretic and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl cotransporter (NKCC1). J Biol Chem. 2012;287(21):17308\u201317.","journal-title":"J Biol Chem"},{"issue":"20","key":"643_CR42","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMra1703100","volume":"377","author":"DH Ellison","year":"2017","unstructured":"Ellison DH, Felker GM. Diuretic treatment in heart failure [published correction appears in N Engl J Med. 2018 Feb 1;378(5):492]. N Engl J Med. 2017;377(20):1964\u201375.","journal-title":"N Engl J Med."},{"issue":"8","key":"643_CR43","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","volume":"13","author":"K Damman","year":"2007","unstructured":"Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13(8):599\u2013608. https:\/\/doi.org\/10.1016\/j.cardfail.2007.04.008.","journal-title":"J Card Fail"},{"issue":"5","key":"643_CR44","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacc.2014.12.010","volume":"65","author":"FH Verbrugge","year":"2015","unstructured":"Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WH, Mullens W. Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol. 2015;65(5):480\u201392.","journal-title":"J Am Coll Cardiol"},{"key":"643_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13925","author":"CM Lombardi","year":"2022","unstructured":"Lombardi CM, Carubelli V, Peveri G, et al. Prognostic significance of serum potassium in patients hospitalized for acute heart failure [published online ahead of print, 2022 May 11]. ESC Heart Fail. 2022. https:\/\/doi.org\/10.1002\/ehf2.13925.","journal-title":"ESC Heart Fail."},{"issue":"1","key":"643_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ehjacc\/zuab097","volume":"11","author":"JJ Cuthbert","year":"2022","unstructured":"Cuthbert JJ, Brown OI, Urbinati A, et al. Hypochloraemia following admission to hospital with heart failure is common and associated with an increased risk of readmission or death: a report from OPERA-HF. Eur Heart J Acute Cardiovasc Care. 2022;11(1):43\u201352. https:\/\/doi.org\/10.1093\/ehjacc\/zuab097.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"9","key":"643_CR47","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cardfail.2016.01.007","volume":"22","author":"LB Cooper","year":"2016","unstructured":"Cooper LB, Mentz RJ, Gallup D, Lala A, DeVore AD, Vader JM, AbouEzzeddine OF, Bart BA, Anstrom KJ, Hernandez AF, Felker GM. Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes. J Card Fail. 2016;22(9):738\u201342.","journal-title":"J Card Fail"},{"issue":"1","key":"643_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10741-019-09851-9","volume":"25","author":"ZL Cox","year":"2020","unstructured":"Cox ZL, Testani JM. Loop diuretic resistance complicating acute heart failure. Heart Fail Rev. 2020;25(1):133\u201345. https:\/\/doi.org\/10.1007\/s10741-019-09851-9.","journal-title":"Heart Fail Rev"},{"issue":"2","key":"643_CR49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40119-020-00194-3","volume":"9","author":"JJ Cuthbert","year":"2020","unstructured":"Cuthbert JJ, Bhandari S, Clark AL. Hypochloraemia in patients with heart failure: causes and consequences. Cardiol Ther. 2020;9(2):333\u201347. https:\/\/doi.org\/10.1007\/s40119-020-00194-3.","journal-title":"Cardiol Ther"},{"issue":"2 Suppl","key":"643_CR50","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1136\/hrt.72.2_Suppl.S40","volume":"72","author":"DC Brater","year":"1994","unstructured":"Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J. 1994;72(2 Suppl):S40\u20133.","journal-title":"Br Heart J"},{"issue":"2 Pt 2","key":"643_CR51","first-page":"R263","volume":"274","author":"J Schnermann","year":"1998","unstructured":"Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol. 1998;274(2 Pt 2):R263\u201379.","journal-title":"Am J Physiol"},{"issue":"4","key":"643_CR52","doi-asserted-by":"publisher","first-page":"676","DOI":"10.2215\/CJN.12391213","volume":"10","author":"LG Palmer","year":"2015","unstructured":"Palmer LG, Schnermann J. Integrated control of Na transport along the nephron. Clin J Am Soc Nephrol. 2015;10(4):676\u201387. https:\/\/doi.org\/10.2215\/CJN.12391213.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"643_CR53","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/oxfordjournals.eurheartj.a059508","volume":"10","author":"IS Anand","year":"1989","unstructured":"Anand IS, Veall N, Kalra GS, et al. Treatment of heart failure with diuretics: body compartments, renal function and plasma hormones. Eur Heart J. 1989;10(5):445\u201350. https:\/\/doi.org\/10.1093\/oxfordjournals.eurheartj.a059508.","journal-title":"Eur Heart J"},{"issue":"1","key":"643_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/hrt.57.1.17","volume":"57","author":"J Bayliss","year":"1987","unstructured":"Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57(1):17\u201322. https:\/\/doi.org\/10.1136\/hrt.57.1.17.","journal-title":"Br Heart J"},{"issue":"11","key":"643_CR55","doi-asserted-by":"publisher","first-page":"e008351","DOI":"10.1161\/CIRCHEARTFAILURE.121.008351","volume":"14","author":"MS Khan","year":"2021","unstructured":"Khan MS, Greene SJ, Hellkamp AS, et al. Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the CHAnge the Management of Patients With Heart Failure Registry. Circ Heart Fail. 2021;14(11):e008351. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008351.","journal-title":"Circ Heart Fail"},{"issue":"14","key":"643_CR56","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jacc.2012.12.043","volume":"61","author":"B Bikdeli","year":"2013","unstructured":"Bikdeli B, Strait KM, Dharmarajan K, et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol. 2013;61(14):1549\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"643_CR57","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/BF00644736","volume":"6","author":"R Henning","year":"1973","unstructured":"Henning R, Lundvall O. Evaluation in man of bumetanide, a new diuretic agent. Eur J Clin Pharmacol. 1973;6(4):224\u20137. https:\/\/doi.org\/10.1007\/BF00644736.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"643_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","volume":"34","author":"H Knauf","year":"1998","unstructured":"Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet. 1998;34(1):1\u201324. https:\/\/doi.org\/10.2165\/00003088-199834010-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"643_CR59","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1185\/03007998809111119","volume":"10","author":"F Ramsay","year":"1988","unstructured":"Ramsay F, Crawford RJ, Allman S, Bailey R, Martin A. An open comparative study of two diuretic combinations, frusemide\/amiloride ('Frumil\u2019) and bumetanide\/potassium chloride (\u201cBurinex\u201d K), in the treatment of congestive cardiac failure in hospital out-patients. Curr Med Res Opin. 1988;10(10):682\u20139. https:\/\/doi.org\/10.1185\/03007998809111119.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"643_CR60","first-page":"473","volume":"22","author":"S Sagar","year":"1984","unstructured":"Sagar S, Sharma BK, Sharma PL, Wahi PL. A comparative randomized double-blind clinical trial of bumetanide and furosemide in congestive cardiac failure and other edema states. Int J Clin Pharmacol Ther Toxicol. 1984;22(9):473\u20138.","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"11","key":"643_CR61","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/j.1552-4604.1981.tb05684.x","volume":"21","author":"LL Konecke","year":"1981","unstructured":"Konecke LL. Clinical trial of bumetanide versus furosemide in patients with congestive heart failure. J Clin Pharmacol. 1981;21(11):688\u201390. https:\/\/doi.org\/10.1002\/j.1552-4604.1981.tb05684.x.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"643_CR62","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/s1388-9842(03)00150-8","volume":"5","author":"K M\u00fcller","year":"2003","unstructured":"M\u00fcller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV\u2013efficacy and quality of life. Eur J Heart Fail. 2003;5(6):793\u2013801. https:\/\/doi.org\/10.1016\/s1388-9842(03)00150-8.","journal-title":"Eur J Heart Fail."},{"issue":"4","key":"643_CR63","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/s1388-9842(02)00122-8","volume":"4","author":"J Cos\u00edn","year":"2002","unstructured":"Cos\u00edn J, D\u00edez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study [published correction appears in Eur J Heart Fail 2002 Oct;4(5):667]. Eur J Heart Fail. 2002;4(4):507\u201313. https:\/\/doi.org\/10.1016\/s1388-9842(02)00122-8.","journal-title":"Eur J Heart Fail."},{"issue":"7","key":"643_CR64","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/s0002-9343(01)00903-2","volume":"111","author":"MD Murray","year":"2001","unstructured":"Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111(7):513\u201320. https:\/\/doi.org\/10.1016\/s0002-9343(01)00903-2.","journal-title":"Am J Med"},{"issue":"3","key":"643_CR65","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1001\/jama.2022.23924","volume":"329","author":"RJ Mentz","year":"2023","unstructured":"\u2022 Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial. JAMA. 2023;329(3):214\u201323. The largest blinded randomised trial of different forms of loop diuretic","journal-title":"JAMA"},{"issue":"289","key":"643_CR66","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijcard.2019.01.109","volume":"15","author":"T T\u00e4ger","year":"2019","unstructured":"T\u00e4ger T, Fr\u00f6hlich H, Grundtvig M, Seiz M, Schellberg D, Goode K, Kazmi S, Hole T, Katus HA, Atar D, Cleland JGF, Agewall S, Clark AL, Frankenstein L. Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - a multicenter propensity score matched analysis. Int J Cardiol. 2019;15(289):83\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.109.","journal-title":"Int J Cardiol"},{"issue":"1","key":"643_CR67","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/01.cir.90.1.220","volume":"90","author":"JM Good","year":"1994","unstructured":"Good JM, Brady AJ, Noormohamed FH, Oakley CM, Cleland JG. Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation. 1994;90(1):220\u20134. https:\/\/doi.org\/10.1161\/01.cir.90.1.220.","journal-title":"Circulation"},{"issue":"3","key":"643_CR68","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ejhf.1402","volume":"21","author":"O Vardeny","year":"2019","unstructured":"Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019;21(3):337\u201341. https:\/\/doi.org\/10.1002\/ejhf.1402.","journal-title":"Eur J Heart Fail"},{"key":"643_CR69","doi-asserted-by":"publisher","unstructured":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).\u00a0Am J Cardiol. 1996;78(8):902\u2013907. https:\/\/doi.org\/10.1016\/s0002-9149(96)00465-1.","DOI":"10.1016\/s0002-9149(96)00465-1"},{"issue":"18","key":"643_CR70","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","volume":"142","author":"NA Mordi","year":"2020","unstructured":"Mordi NA, Mordi IR, Singh JS, McCrimmon RJ, Struthers AD, Lang CC. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial [published correction appears in Circulation. 2020 Nov 3;142(18):e316]. Circulation. 2020;142(18):1713\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048739.","journal-title":"Circulation."},{"issue":"5","key":"643_CR71","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ejheart.2004.09.006","volume":"7","author":"E Galve","year":"2005","unstructured":"Galve E, Mallol A, Catalan R, et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. Eur J Heart Fail. 2005;7(5):892\u20138. https:\/\/doi.org\/10.1016\/j.ejheart.2004.09.006.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"643_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s1388-9842(02)00205-2","volume":"5","author":"DJ van Kraaij","year":"2003","unstructured":"van Kraaij DJ, Jansen RW, Sweep FC, Hoefnagels WH. Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. Eur J Heart Fail. 2003;5(1):47\u201353. https:\/\/doi.org\/10.1016\/s1388-9842(02)00205-2.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"643_CR73","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ejhf.748","volume":"19","author":"S Dovancescu","year":"2017","unstructured":"Dovancescu S, Pellicori P, Mabote T, Torabi A, Clark AL, Cleland JGF. The effects of short-term omission of daily medication on the pathophysiology of heart failure. Eur J Heart Fail. 2017;19(5):643\u20139. https:\/\/doi.org\/10.1002\/ejhf.748.","journal-title":"Eur J Heart Fail"},{"issue":"44","key":"643_CR74","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1093\/eurheartj\/ehz554","volume":"40","author":"LE Rohde","year":"2019","unstructured":"Rohde LE, Rover MM, Figueiredo Neto JA, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur Heart J. 2019;40(44):3605\u201312.","journal-title":"Eur Heart J"},{"key":"643_CR75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ahj.2003.08.012","volume":"147","author":"J Butler","year":"2004","unstructured":"Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331\u20138.","journal-title":"Am Heart J"},{"key":"643_CR76","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.ejheart.2007.07.011","volume":"9","author":"V Hasselblad","year":"2007","unstructured":"Hasselblad V, Stough WG, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064\u2013106.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"643_CR77","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00392-022-02126-8","volume":"112","author":"V Nuzzi","year":"2023","unstructured":"Nuzzi V, Cannat\u00e0 A, Pellicori P, et al. Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications [published correction appears in Clin Res Cardiol. 2022 Dec 6;:]. Clin Res Cardiol. 2023;112(3):419\u201330. https:\/\/doi.org\/10.1007\/s00392-022-02126-8.","journal-title":"Clin Res Cardiol."},{"issue":"6","key":"643_CR78","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.amjmed.2020.11.019","volume":"134","author":"C Faselis","year":"2021","unstructured":"Faselis C, Lam PH, Patel S, et al. Loop diuretic prescription and long-term outcomes in heart failure: association modification by congestion. Am J Med. 2021;134(6):797\u2013804. https:\/\/doi.org\/10.1016\/j.amjmed.2020.11.019.","journal-title":"Am J Med"},{"issue":"6","key":"643_CR79","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2020.06.022","volume":"76","author":"C Faselis","year":"2020","unstructured":"Faselis C, Arundel C, Patel S, et al. Loop diuretic prescription and 30-day outcomes in older patients with heart failure. J Am Coll Cardiol. 2020;76(6):669\u201379. https:\/\/doi.org\/10.1016\/j.jacc.2020.06.022.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"643_CR80","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00392-020-01779-7","volume":"110","author":"J Simonavi\u010dius","year":"2021","unstructured":"Simonavi\u010dius J, Maeder MT, Eurlings CGMJ, et al. Intensification of pharmacological decongestion but not the actual daily loop diuretic dose predicts worse chronic heart failure outcome: insights from TIME-CHF. Clin Res Cardiol. 2021;110(8):1221\u201333. https:\/\/doi.org\/10.1007\/s00392-020-01779-7.","journal-title":"Clin Res Cardiol"},{"key":"643_CR81","unstructured":"National Institute for Health and Care Excellence. Acute heart failure: diagnosis and management. Clinical guideline [CG187]. November 2021. Available from: https:\/\/www.nice.org.uk\/guidance\/cg187 . Accessed 1\/7\/2022."},{"issue":"3","key":"643_CR82","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ejhf.235","volume":"17","author":"AD DeVore","year":"2015","unstructured":"DeVore AD, Hasselblad V, Mentz RJ, et al. Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2015;17(3):340\u20136. https:\/\/doi.org\/10.1002\/ejhf.235.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"643_CR83","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","volume":"2","author":"J Butler","year":"2017","unstructured":"Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2017.2198.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"643_CR84","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa1005419.","journal-title":"N Engl J Med"},{"issue":"11","key":"643_CR85","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","volume":"69","author":"GM Felker","year":"2017","unstructured":"Felker GM, Mentz RJ, Cole RT, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399\u2013406. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.004.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"643_CR86","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ejhf.1492","volume":"21","author":"O Chioncel","year":"2019","unstructured":"Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, Piepoli MF, Crespo-Leiro MG, Lainscak M, Ponikowski P, Filippatos G, Ruschitzka F, Seferovic P, Coats AJS, Lund LH, ESC-EORP-HFA Heart Failure Long-Term Registry Investigators. Acute heart failure congestion and perfusion status\u00a0-\u00a0impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338\u201352. https:\/\/doi.org\/10.1002\/ejhf.1492.","journal-title":"Eur J Heart Fail."},{"issue":"11","key":"643_CR87","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jchf.2020.05.013","volume":"8","author":"SJ Greene","year":"2020","unstructured":"Greene SJ, Triana TS, Ionescu-Ittu R, et al. In-hospital therapy for heart failure with reduced ejection fraction in the United States. JACC Heart Fail. 2020;8(11):943\u201353. https:\/\/doi.org\/10.1016\/j.jchf.2020.05.013.","journal-title":"JACC Heart Fail"},{"issue":"9","key":"643_CR88","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1056\/NEJMoa1005419","volume":"364","author":"GM Felker","year":"2011","unstructured":"Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O\u2019Connor CM, NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797\u2013805.","journal-title":"N Engl J Med."},{"issue":"5","key":"643_CR89","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1161\/CIRCHEARTFAILURE.114.001377","volume":"7","author":"FH Verbrugge","year":"2014","unstructured":"Verbrugge FH, Nijst P, Dupont M, Penders J, Tang WH, Mullens W. Urinary composition during decongestive treatment in heart failure with reduced ejection fraction. Circ Heart Fail. 2014;7(5):766\u201372. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001377.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"643_CR90","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00392-019-01521-y","volume":"109","author":"S Frea","year":"2020","unstructured":"Frea S, Pidello S, Volpe A, Canavosio FG, Galluzzo A, Bovolo V, Camarda A, Golzio PG, D\u2019Ascenzo F, Bergerone S, Rinaldi M, Gaita F. Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial. Clin Res Cardiol. 2020;109(4):417\u201325.","journal-title":"Clin Res Cardiol."},{"issue":"2","key":"643_CR91","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/anae.14038","volume":"73","author":"KT Ng","year":"2018","unstructured":"Ng KT, Yap JLL. Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials. Anaesthesia. 2018;73(2):238\u201347.","journal-title":"Anaesthesia."},{"issue":"24","key":"643_CR92","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","volume":"367","author":"BA Bart","year":"2012","unstructured":"Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367(24):2296\u2013304. https:\/\/doi.org\/10.1056\/NEJMoa1210357.","journal-title":"N Engl J Med"},{"issue":"2","key":"643_CR93","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ejhf.2385","volume":"24","author":"JM Ter Maaten","year":"2022","unstructured":"Ter Maaten JM, Beldhuis IE, van der Meer P, et al. Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial. Eur J Heart Fail. 2022;24(2):385\u201392. https:\/\/doi.org\/10.1002\/ejhf.2385.","journal-title":"Eur J Heart Fail"},{"key":"643_CR94","doi-asserted-by":"publisher","first-page":"l359","DOI":"10.1136\/bmj.l359","volume":"364","author":"SD Anisman","year":"2019","unstructured":"Anisman SD, Erickson SB, Morden NE. How to prescribe loop diuretics in oedema. BMJ. 2019;364:l359. https:\/\/doi.org\/10.1136\/bmj.l359. Published 2019 Feb 21.","journal-title":"BMJ."},{"issue":"4","key":"643_CR95","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/2048872618768488","volume":"7","author":"FH Verbrugge","year":"2018","unstructured":"Verbrugge FH. Editor\u2019s choice-diuretic resistance in acute heart failure. Eur Heart J Acute Cardiovasc Care. 2018;7(4):379\u201389. https:\/\/doi.org\/10.1177\/2048872618768488.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"2","key":"643_CR96","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(2):137\u201355. https:\/\/doi.org\/10.1002\/ejhf.1369.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"643_CR97","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ehjqcco\/qcac007","volume":"8","author":"M Khorramshahi Bayat","year":"2022","unstructured":"Khorramshahi Bayat M, Ngo L, Mulligan A, Chan W, McKenzie S, Hay K, Ranasinghe I. The association between urinary sodium concentration (UNa) and outcomes of acute heart failure: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2022;8(7):709\u201321. https:\/\/doi.org\/10.1093\/ehjqcco\/qcac007.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"643_CR98","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ejhf.1428","volume":"21","author":"J Biegus","year":"2019","unstructured":"Biegus J, Zymli\u0144ski R, Sokolski M, Todd J, Cotter G, Metra M, et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail. 2019;21:624\u201333.","journal-title":"Eur J Heart Fail"},{"key":"643_CR99","doi-asserted-by":"publisher","first-page":"e002370","DOI":"10.1161\/CIRCHEARTFAILURE.115.002370","volume":"9","author":"JM Testani","year":"2016","unstructured":"Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail. 2016;9:e002370.","journal-title":"Circ Heart Fail"},{"key":"643_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02532-z","author":"JM ter Maaten","year":"2023","unstructured":"\u2022 ter Maaten JM, Beldhuis IE, van der Meer P, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial [published online ahead of print, 2023 Aug 28]. Nat Med. 2023. https:\/\/doi.org\/10.1038\/s41591-023-02532-z. Randomised trial of natriuresis-guided loop diuretic treatment","journal-title":"Nat Med."},{"issue":"6","key":"643_CR101","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1002\/ehf2.13666","volume":"8","author":"J Dauw","year":"2021","unstructured":"Dauw J, Lelonek M, Zegri-Reiriz I, et al. Rationale and design of the efficacy of a standardized diuretic protocol in acute heart failure study. ESC Heart Fail. 2021;8(6):4685\u201392.","journal-title":"ESC Heart Fail"},{"issue":"9","key":"643_CR102","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/qjmed\/hcaa114","volume":"113","author":"A Ioannou","year":"2020","unstructured":"Ioannou A, Browne T, Jordan S, Metaxa S, Mandal AKJ, Missouris CG. Diuretic lounge and the impact on hospital admissions for treatment of decompensated heart failure. QJM. 2020;113(9):651\u20136. https:\/\/doi.org\/10.1093\/qjmed\/hcaa114.","journal-title":"QJM"},{"issue":"12","key":"643_CR103","doi-asserted-by":"publisher","first-page":"599","DOI":"10.12968\/bjcn.2021.26.12.599","volume":"26","author":"D Payne","year":"2021","unstructured":"Payne D. Intravenous diuretic administration in the home environment. Br J Community Nurs. 2021;26(12):599\u2013603. https:\/\/doi.org\/10.12968\/bjcn.2021.26.12.599.","journal-title":"Br J Community Nurs"},{"issue":"3","key":"643_CR104","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ejheart.2008.01.003","volume":"10","author":"M Ryder","year":"2008","unstructured":"Ryder M, Murphy NF, McCaffrey D, O\u2019Loughlin C, Ledwidge M, McDonald K. Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. Eur J Heart Fail. 2008;10(3):267\u201372. https:\/\/doi.org\/10.1016\/j.ejheart.2008.01.003.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"643_CR105","doi-asserted-by":"publisher","first-page":"528","DOI":"10.12968\/bjcn.2013.18.11.528","volume":"18","author":"J Austin","year":"2013","unstructured":"Austin J, Hockey D, Williams WR, Hutchison S. Assessing parenteral diuretic treatment of decompensated heart failure in the community. Br J Community Nurs. 2013;18(11):528\u201334. https:\/\/doi.org\/10.12968\/bjcn.2013.18.11.528.","journal-title":"Br J Community Nurs"},{"issue":"7","key":"643_CR106","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/00015385.2023.2197834","volume":"78","author":"KYK Wong","year":"2023","unstructured":"Wong KYK, Hughes DA, Debski M, et al. Effectiveness of out-patient based acute heart failure care: a pilot randomised controlled trial. Acta Cardiol. 2023;78(7):828\u201337. https:\/\/doi.org\/10.1080\/00015385.2023.2197834.","journal-title":"Acta Cardiol"},{"issue":"suppl 2","key":"643_CR107","doi-asserted-by":"publisher","first-page":"A74","DOI":"10.1136\/heartjnl-2020-BCS.96","volume":"106","author":"K Wong","year":"2020","unstructured":"Wong K, Latt NKZ, Debski M, et al. Safety and effectiveness of outpatient based acute heart failure care: a randomised controlled feasibility trial. Heart. 2020;106(suppl 2):A74\u20135. https:\/\/doi.org\/10.1136\/heartjnl-2020-BCS.96.","journal-title":"Heart"},{"issue":"1","key":"643_CR108","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/bmjspcare-2020-002803","volume":"13","author":"F Birch","year":"2023","unstructured":"Birch F, Boam E, Parsons S, Ghosh J, Johnson MJ. Subcutaneous furosemide in advanced heart failure: service improvement project. BMJ Support Palliat Care. 2023;13(1):112\u20136. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002803.","journal-title":"BMJ Support Palliat Care"},{"issue":"1","key":"643_CR109","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2017.10.001","volume":"6","author":"NA Gilotra","year":"2018","unstructured":"Gilotra NA, Princewill O, Marino B, et al. Efficacy of Intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6(1):65\u201370. https:\/\/doi.org\/10.1016\/j.jchf.2017.10.001.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"643_CR110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jacbts.2017.10.001","volume":"3","author":"DA Sica","year":"2018","unstructured":"Sica DA, Muntendam P, Myers RL, et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci. 2018;3(1):25\u201334. https:\/\/doi.org\/10.1016\/j.jacbts.2017.10.001. Published 2018 Feb 7.","journal-title":"JACC Basic Transl Sci."},{"key":"643_CR111","doi-asserted-by":"publisher","unstructured":"Osmanska J, Brooksbank K, Docherty KF, et al. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies [published online ahead of print, 2023 Oct 6].\u00a0Eur Heart J Cardiovasc Pharmacother. 2023;pvad073. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad073.","DOI":"10.1093\/ehjcvp\/pvad073"},{"key":"643_CR112","unstructured":"National Health Service. Health Regulation Authority. Planning and improving research. SUBCUT-HF II. 2022. Available from: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/subcut-hf-ii\/ . Accessed 22\/09\/2023."}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-024-00643-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-024-00643-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T02:15:16Z","timestamp":1709864116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-024-00643-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["643"],"URL":"https:\/\/doi.org\/10.1007\/s11897-024-00643-3","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]},"assertion":[{"value":"3 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}